AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting-edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology and eradication. Joint plenary sessions with the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis will highlight common topics of interest including mechanisms of virus entry and inhibition, and will significantly enhance opportunities for interdisciplinary interactions. Leaders from the HIV replication and drug resistance fields will critically examine the state of antiviral therapy, novel inhibitors and important virus-host interactions. Speakers selected from submitted abstracts will fill out workshops on pharmacological approaches and the cell biology of HIV infection.

This meeting is held jointly with the Keystone Symposia meeting "Cell Biology of Virus Entry, Replication and Pathogenesis." Registering for one meeting in a set of joint meetings enables participation in sessions of the other, pending space availability. Other deadlines: Global Health Travel Award - October 25, 2011 Abstract & scholarship - November 29, 2011 Late-breaking abstract - January 4, 2012